Biorestorative Therapies, Inc. BRTX
2.55
0.04
1.59%
as of 25 Sep
- Market cap
- $3.5M
- P/E
- 0.0×
Follow BRTX
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.67 | 1.48 | 1.72 | 1.21 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.06) | (0.22) | (0.23) | (0.27) | |
P/B ratio |
0.08 | 1.55 | 0.30 | 0.15 | |
Price to Tangible BV |
0.10 | 0.00 | 0.40 | 0.17 | |
EV/Sales |
(9.25) | (6.62) | (9.88) | (10.92) | |
EV/EBITDA |
0.24 | 0.15 | 0.26 | 0.51 | |
EV/Operating CF |
0.28 | 0.22 | 0.35 | 0.69 | |
EV/FCF |
0.25 | 0.20 | 0.32 | 0.61 | |
Quick Ratio |
2.23 | 0.80 | 1.31 | 2.01 | |
Current Ratio |
2.35 | 0.84 | 1.37 | 2.07 | |
Net Debt/EBITDA |
1.08 | 0.78 | 1.23 | 2.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.04 | 0.04 | 0.05 | |
Operating CF/Net income |
1.77 | 0.75 | 0.95 | 1.01 | |
Capex/Depreciation |
0.00 | (1.51) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8,303.02% | 13,403.57% | 21,989.83% | 733.89% | |
Selling, General and Administrative Expense of Revenue |
6,358.62% | 6,204.59% | 9,453.39% | 453.02% | |
Intangible Assets out of Total Assets |
0.11 | 0.13 | 0.10 | 0.07 | |
Share Based Compensation of Revenue |
1,250.86% | 2,284.69% | 3,389.83% | 154.53% | |
Graham Net Nets |
9.13 | (1.10) | 1.92 | 5.38 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7,925.93%) | (2,694.92%) | (2,027.59%) | (1,520.96%) | |
Free Cash Flow Yield |
(5,477.46%) | (2,276.49%) | (1,807.42%) | (1,480.21%) | |
Revenue per Share |
0.03 | 0.04 | 0.03 | 0.69 | |
Operating CF per Share |
(4.30) | (5.37) | (6.36) | (6.16) | |
Capex per Share |
0.00 | (0.18) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.30) | (5.55) | (6.36) | (6.16) | |
Cash per Share |
4.05 | 6.57 | 9.85 | 16.89 | |
Shareholders Equity per Share |
3.41 | 0.79 | 4.84 | 11.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.41 | 0.79 | 4.84 | 11.09 | |
Free Cash Flow |
(3.81) | (2.49) | (2.90) | (2.69) | |
Working Capital |
2.19 | (0.59) | 1.27 | 3.93 | |
Capital Expenditures |
— | (0.08) | 0.00 | 0.00 | |
Net Current Asset Value |
2.19 | (0.59) | 1.27 | 3.93 | |
EV/EBIT |
0.23 | 0.15 | 0.26 | 0.50 | |
Capex to Sales |
0.00 | 4.07 | 0.00 | 0.00 | |
Net Profit Margin |
(9,286.21%) | (16,365.31%) | (25,748.31%) | (875.80%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.10 | 0.09 | 0.02 | |
Average Payables |
0.63 | 0.91 | 0.63 | 0.41 | |
Average Assets |
7.48 | 8.18 | 10.11 | 12.32 | |
Average Common Equity |
4.58 | 4.43 | 6.09 | 7.81 |
Columns are period end dates